Jcr Pharmaceuticals Co., Ltd. · TSE:4552

Jcr Pharmaceuticals — H1 FY2021 Earnings Presentation

14 slides from Jcr Pharmaceuticals's earnings presentation, Nov 2, 2021

  1. Slide 1: FY2021 First-Half results Briefing Session

    FY2021 First-Half results Briefing Session Financial Results –Six Months Ended Sep.30, 2021 (2Q FY2021) November 2, 2021 JCR Pharmaceuticals co., Ltd. 【Securities code】4552, 1st Sec. TSE Copyright © 2021 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  2. Slide 2: Financial Highlights (2Q FY2021 results)

    Financial Highlights (2Q FY2021 results) Net sales and income exceeded the results of the same period of the previous year. Unit：million yen Progress rate against Results Year-on-year full-year revised forecast Net sales 28,383 +159.2％ 54.6％ 2Q FY2021 Operating Income 13,640 +943.3％ 62.9％ Ordinary I

  3. Slide 3: Consolidated Results

    Consolidated Results Unit：million yen Six Months Ended Sep. 30, 2021 FY2021 (Apr. 1, 2021- Mar. 31, 2022) ◆Net Sales 13,640 million yen Six Months Ended Year-on-year: +12,333 million yen Consolidated Forecast Progress Sep. 30, 2020 A Year-on-year (revised) rate Six Months Ended Sep. 30, 2020 +1,307

  4. Slide 4: Breakdown of net sales (Consolidated)

    Breakdown of net sales (Consolidated) Unit：million yen FY2021 ◆Net sales 28,383 million yen Six Months Ended Six Months Ended Sep. 30, 2020 Sep. 30 2021 (Apr. 1, 2021- Year-on-year ＋17,432million yen Mar. 31, 2022) Forecast Progress Six Months Ended Sep. 30, 2020 +10,951 Composition Composition rati

  5. Slide 5: Net sales by each core product

    Net sales by each core product Unit：million yen GROWJECT® Epoetin Alpha BS Inj.[JCR], Darbepoetin Alpha BS Inj.[JCR] Epoetin Alpha BS Darbepoetin Alpha BS 13,900 13,256 12,650 11,978 Topics • Oct. 2020: 3809 Topics 6,689 Change in sales 1,412 3,700 • Apr.-May 2021: structure Epoetin Alpha BS • Oct.

  6. Slide 6: IZCARGO Sales Trends

    IZCARGOⓇ Sales Trends Unit：million yen 1000 985 900 251 800 Topics • Mya 19, 2021: Newly 700 launched • Establishment of a 600 291 dedicated team for 500 lysosomal diseases within the Marketing 400 Department to provide 219 professional support for 300 information provision 200 activities related to

  7. Slide 7: Changes in sales (Except AZD1222 stock solution)

    Changes in sales (Except AZD1222 stock solution） Products* sales License Revenue Unit：million yen *Products: GROWJECTⓇ, IZCARGO Ⓡ, Treatment for renal anemia, TEMCELL Ⓡ, Agalsidase Beta BS[JCR], Other 10,200 6,406 2,050 3,560 2,137 7,557 27,100 22,731 23,275 18,457 19,600 12,779 FY2017 FY2018 FY2019

  8. Slide 8: Balance sheet (Consolidated)

    Balance sheet (Consolidated) Unit：million yen Change Change Mar. 2021 Sep. 2021 Mar. 2021 Sep. 2021 ・ Main change ・ Main change Total ＋6,558 ・ Special suspense account Total ＋9,876 Current for tax purpose reduction ・ Cash and deposits 29,028 35,586 entry liabilities ＋4,345 Current (5,848) 48,545 58,

  9. Slide 9: Cash Flows (Consolidated)

    Unit：million yen Cash Flows (Consolidated) Six Months Ended Six Months Ended Year-on-year Operating Activities Sep. 30, 2020 A Sep. 30, 2021 B Ｂ-Ａ Investing Activities Income before income taxes 1,381 12,729 11,348 Financing Activities Depreciation and amortization 872 922 49 Cash and Cash Equivalen

  10. Slide 10: FORWARD-LOOKING STATEMENT

    FORWARD- LOOKING STATEMENT This presentation contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are outside our control. All forward- looking statements regarding our plans, outlook, strategy and future performance are based on judgments derive

  11. Slide 11: Copyright © 2021 JCR Pharmaceuticals Co., Ltd. All rights reserved.

    Copyright © 2021 JCR Pharmaceuticals Co., Ltd. All rights reserved.

  12. Slide 12: Changes in sales breakdown (Consolidated)

    Changes in sales breakdown (Consolidated) 23,898 Unit：million yen 8,046 AZD1222 bulk 14,834 51 404 Other 11 License Revenue 7,557 Agalsidase Beta BS 8,817 6,396 9,084 TEMCELL 8,063 1,051 7 Darbepoetin Alpha BS 7,508 773 7,438 323 1,048 10 250 74 194 1,656 1,717 2,506 1,002 220 Epoetin Alpha BS 219 1

  13. Slide 13: Changes in composition ratio of cost/expense

    Changes in composition ratio of cost/expense Unit：million yen Operating Income R&D SG&A Cost of sales 15.8% 29.8% 28.4% 26.0% 4,485 31.9% 32.1% 6,128 6,567 7,812 7,901 3,513 23.7% 6,737 28.7% 31.4% 31.4% 12.4% 30.8% 8,643 7,270 34.0% 6,469 7,638 3,520 3,723 Above number (％) 17.8% rate of sales 18.8%

  14. Slide 14: Correlation between R&D expenses and main R&D pipeline

    Unit：million yen Correlation between R&D expenses and main R&D pipeline 11,080 Preclinical R&D Expenses (before deducting) 4Q 2Q 6,582 Clinical 5,270 5,856 4,865 Filed an application Approved 2,158 2,407 3,539 2,607 3,570 FY2017 FY2018 FY2019 FY2020 FY2021 JR-141(Japan) JR-141(Brazil) JR-141(Global）

JCR Pharmaceuticals — H1 FY2021 Earnings Presentation on 6ix